

Contents

Preface *xi*

- 1 Extracellular Vesicles and Their Biomedical Applications: An Overview 1**
Xing-Jie Liang, Ke Cheng, and Zhenhua Li
 - 1.1 Introduction 1
 - 1.2 Biogenesis and Composition of Extracellular Vesicles 1
 - 1.3 Biological Functions of Extracellular Vesicles 2
 - 1.4 Extracellular Vesicles Isolation and Limitations 3

- 2 Biogenesis and Identification of Extracellular Vesicles 5**
Dandan Ding, Xing Zhang, Yu Zhao, Xiaoya Li, Qingqing Leng, and Zhenhua Li
 - 2.1 Biogenesis of Extracellular Vesicles 5
 - 2.1.1 Biogenesis of Exosome 6
 - 2.1.2 Biogenesis of Microvesicle 8
 - 2.1.3 Biogenesis of Apoptotic Bodies 8
 - 2.1.4 Biogenesis of Large Oncosomes 9
 - 2.2 Identification of Extracellular Vesicles 9
 - 2.2.1 Electron Microscopic Identification 9
 - 2.2.1.1 Scanning Electron Microscopy 9
 - 2.2.1.2 Transmission Electron Microscopy 10
 - 2.2.1.3 Atomic Force Microscopy 11
 - 2.2.1.4 Cryo-Electron Microscopy 12
 - 2.2.2 Particle Size Detection 13
 - 2.2.2.1 Nanoparticle Tracking Analysis 13
 - 2.2.2.2 Dynamic Light Scattering 14
 - 2.2.3 Surface Protein Assay 16
 - 2.2.3.1 Protein Immunoblotting Method 17
 - 2.2.3.2 Nano-Flow Cytometry 19
 - 2.2.3.3 Enzyme-Linked Immunosorbent Assay 19
 - 2.2.4 Other Methods 21
 - 2.2.4.1 Tunable Resistive Pulse Sensing 21

- 2.2.4.2 Single EV Analysis Technique 22
- 2.2.4.3 Micronuclear Magnetic Resonance 23
- References 24

3 Therapeutic Potential of Extracellular Vesicles from Different Cell Sources 35

Xueyi Wang and Zhenhua Li

- 3.1 Extracellular Vesicles Derived from Stem Cells (SCs) 35
 - 3.1.1 Extracellular Vesicles Derived from Mesenchymal Stem Cells (MSCs) 37
 - 3.1.1.1 Kidney Injury 38
 - 3.1.1.2 Myocardial Ischemia/Reperfusion Injury (MI/RI) 38
 - 3.1.1.3 Spinal Cord Injury (SCI) 39
 - 3.1.1.4 Cancer 40
 - 3.1.2 Extracellular Vesicles Derived from Neural Stem Cells (NSCs) 40
 - 3.1.3 Extracellular Vesicles Derived from Endothelial Progenitor Cells (EPCs) 41
 - 3.1.4 Extracellular Vesicles Derived from Cardiac Progenitor Cells (CPCs) and Other Stem Cells 41
- 3.2 Extracellular Vesicles Derived from Immune Cells 42
 - 3.2.1 Extracellular Vesicles Derived from Macrophages 42
 - 3.2.2 Extracellular Vesicles Derived from Dendritic Cells (DCs) 44
 - 3.2.3 Extracellular Vesicles Derived from T Cells 45
 - 3.2.4 Extracellular Vesicles Derived from Natural Killer (NK) Cells 46
- 3.3 Extracellular Vesicles Derived from Cancer Cells 47
- 3.4 Extracellular Vesicles Derived from Plants 49
 - 3.4.1 Anti-inflammatory 49
 - 3.4.2 Anticancer 50
 - 3.4.3 Antibacterial 51
 - 3.4.4 Antioxidation 51
- References 51

4 Biomedical Applications of Extracellular Vesicles in Treatment of Disease 59

Fei Wang, Jiacong Ai, Ziyang Zhang, Yuanhang Li, and Zhenhua Li

- 4.1 Tissue Engineering and Regenerative Medicine 60
- 4.2 Metabolic Diseases 67
- 4.3 Cardiovascular Diseases 74
- 4.4 Respiratory Diseases 85
- 4.5 Cancers 88
- 4.6 Conclusion and Perspectives 93
- References 94

5	Applications of Engineered Extracellular Vesicles	101
	<i>Lanya Li, Yingxian Xiao, Shushan Mo, and Zhenhua Li</i>	
5.1	Engineering EVs for Cargo Loading	101
5.1.1	Endogenous Loading	101
5.1.2	Exogenous Loading	104
5.2	Engineering EVs for Surface Modification	106
5.2.1	Genetic Engineering	106
5.2.2	Chemical Modification	108
5.2.3	Hydrophobic Membrane Engineering	109
	References	111
6	Current Technology for Production, Isolation, and Quality Control of Extracellular Vesicles	117
	<i>Dandan Han, Yichuan Ma, Yujing Hu, and Zhenhua Li</i>	
6.1	Production of EVs	117
6.1.1	Three-Dimensional Culture	117
6.1.2	Physical Stimulation	119
6.1.3	Chemical Stimulation	120
6.1.4	Physiological Modification	120
6.1.5	Genetic Manipulation	121
6.2	Extraction of EVs	122
6.2.1	Separation Strategies of EVs	123
6.2.2	Ultracentrifugation Approach	123
6.2.2.1	Differential Ultracentrifugation	123
6.2.2.2	Isopycnic and Moving-Zone Density Gradient Ultracentrifugation	125
6.2.3	Ultrafiltration Approach	125
6.2.4	Size-Exclusion Chromatography	127
6.2.5	Polymer Precipitation Strategy	128
6.2.6	Immunoaffinity Capture Approach	128
6.2.7	Microfluidic Technology	129
6.2.8	Other Methods	131
6.3	Quality Control of EVs	132
6.3.1	Transmission Electron Microscopy	133
6.3.2	High-Resolution Liquid Chromatography–Mass Spectrometry	134
6.3.3	Enzyme-Linked Immunosorbent Assay	134
6.3.4	Fourier-Transform Infrared Attenuated Total Reflection Spectroscopy	135
6.3.5	Capillary Electrophoresis	135
6.3.6	Nanoparticles Tracking Analysis	136
6.3.7	Flow Cytometer	137
6.3.8	Other Techniques	138
	References	140

7	Prospects and Limitations of Clinical Application of Extracellular Vesicles	147
	<i>Li Luo, Weirun Li, and Zhenhua Li</i>	
7.1	Application of Exosomes as Liquid Biopsy in Clinical Diagnosis	147
7.2	Exosomes—It has Become a Star Molecule in Disease Diagnosis	147
7.2.1	Exosomes Could Be Used as Prognostic and Diagnostic Biomarkers in Cancer	150
7.2.2	Exosomes Biopsy Strategies were Proposed to Target the Different Cancers	152
7.2.2.1	Pancreatic Cancer	152
7.2.2.2	Gastric Cancer	152
7.2.2.3	Lung Cancer	152
7.2.2.4	Breast Cancer	153
7.2.2.5	Liver Cancer	153
7.2.2.6	Ovarian Cancer	153
7.2.2.7	Melanoma	154
7.2.2.8	Colon Cancer	154
7.2.2.9	Glioma	155
7.2.3	Exosomes in Clinical Trial for Cancer Biopsy	155
7.3	The Commercial Application of Exosomes	158
7.3.1	Tumor Therapy	158
7.3.2	Lung Infection and ARDS Treatment	158
7.3.3	Cardiovascular Disease Treatment	160
7.3.4	Liver and Kidney Injury Treatment	160
7.3.5	Ophthalmology Treatment	160
7.3.6	Cartilage Injury Treatment	161
7.3.7	Other Treatments	161
7.3.8	Engineering of Exosome Delivery	161
7.3.9	Skin Repair and Medical Skincare Products	164
7.4	Commercial Development of Exosomes	166
7.4.1	Analysis of Representative Companies of Exosomes	168
7.4.1.1	ExoCoBio	168
7.4.1.2	Direct Biologics	168
7.4.1.3	Tianjin Exocrine Science and Technology	169
7.4.1.4	TheraXyte	170
7.4.1.5	Exosome Diagnostics	170
7.4.1.6	Codiak	171
7.4.1.7	Evox	171
7.4.1.8	EVerZom	171
7.5	Issues and Challenges	172
7.5.1	Quality Control	172
7.5.2	Storage Stability	172
7.5.3	Product Safety	173
7.5.4	Drug-Forming Properties of Engineered Exosomes	173
	References	174

8	Conclusion and Future Perspectives	181
	<i>Xing-Jie Liang, Ke Cheng, and Zhenhua Li</i>	
8.1	Summary and Conclusions	181
8.2	General Trends and Developments	182
8.2.1	EVs in Drug Delivery	182
8.2.2	Engineered EVs in Biomedical Applications	183
8.2.3	EVs for Clinical Applications When Comparing with Liposomes	184
8.3	Challenges for Future Research	185
8.3.1	Standardization and Quality Control	185
8.3.2	Scalability and Manufacturing	185
8.3.3	Targeting and Biodistribution	186
8.3.4	Safety and Toxicity	186
8.3.5	Regulatory Challenges	186
8.3.6	Heterogeneity of EV Populations	187
8.3.7	Understanding the Role of EVs in Disease Progression and Development	187
	Index	189

